Healthcare & Pharmaceuticals

Effective advice built on strong foundations

Healthcare and pharmaceutical companies come to our law firm not just because we have the right expertise or the best people, but because we put in the work it takes to understand the sector.

With scientific advances, ever-changing government regulation, as well as strict ethical considerations, navigating healthcare legislation is rarely straightforward. So we make sure our legal advice is based on a comprehensive knowledge of current developments in the industry. We scour the legal and commercial developments in pharmaceuticals and in medicine as they happen, and we host annual seminars for our clients so that they, and we, can stay at the cutting edge.

Areas of law we advise pharmaceutical and healthcare clients on include intellectual property, regulation, commercial, competition and corporate law. We know that sometimes you will have to move fast to get a deal done, or to respond to an issue, so we focus on making sure you get a straight answer quickly.

Our lawyers advise companies working in:

  • Pharmaceuticals – including originators and generics
  • Biotechnology
  • Research and Development
  • Medical Devices
  • Health Insurance
  • Health Services Provision
  • Hospitals and Medical Facilities
  • Aged Care and Retirement Villages

We also advise private equity firms, investors and financial advisers to the sector.

Latest Thinking

Insight

The complexities and challenges of getting doctor incentives right

With intense competition for medical talent in the Australian market driven by a shortage of doctors across all specialities and burgeoning healthcare demands, it is absolutely critical for private healthcare providers who rely on doctors’ services - and the financial sponsors who invest in those providers - to structure effective incentives for attracting and retaining doctors.

21 October 2022

Insight

The Asian healthcare revolution – How healthcare markets in Asia are transforming and the opportunities for private capital

From growth capital, to some of the largest global Private Equity (PE)and infrastructure funds, to sovereign wealth funds, private capital of all forms has been increasingly deployed in Asian healthcare assets.

21 October 2022

Insight

Healthcare as an infrastructure investment?

The healthcare industry’s economic resilience – a product of macroeconomic, demographic and industry factors - is attracting ever-increasing amounts of private capital investment and a diverse range of investors with a broader range of strategies and investment mandates.

21 October 2022

Insight

Changing models of care – a snapshot

Hospitals and healthcare systems, both in Australia and around the world, face continued pressure to provide high quality services in a health environment characterised by funding constraints, rapidly rising costs, continuing access inequity, and increasing staff shortages.

21 October 2022

Insight

More widespread reforms for Aged Care – the key changes for investors

Private capital has long been attracted to investment in the aged care sector. Demographic shifts which ensure ever-growing demand, government funding and relative flexibility to invest refundable deposit or accommodation bonds (RADs) over the life of a residency have made it an attractive and stable sector for traditional private equity, infrastructure and real estate investors.

21 October 2022

Publication

Investing in China’s ‘internet hospitals’: twists, turns and why structure matters

Covid provoked a surge worldwide in the use of technology to deliver healthcare services and products.

18 August 2022

Insight

China relaxes rules on lab-developed tests – but uncertainties remain

New regulations in China designed to encourage innovation in clinical trials have made it easier to test human samples in a lab setting.

19 May 2022

Show More Show Less

Latest News

Deals

KWM advises Icon on joint venture in Malaysia

King & Wood Mallesons (KWM) is delighted to have advised Icon Group (Icon) on its joint venture with Sunsuria. Icon is a leading provider of comprehensive cancer care, owned by one of the largest private equity firms in Asia, BPEA-EQT.

18 September 2023

Our Experts in Healthcare & Pharmaceuticals

Searching
SG | EN
Current site :    SG   |   EN
Australia
Singapore